Navigation Links
EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
Date:9/8/2010

xpectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Contact:Ginny DunnAssociate DirectorCorporate Communications & Investor Relations 240-864-2643
'/>"/>
SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
2. EntreMed Reports Second Quarter 2010 Financial Results
3. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
4. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
5. EntreMed Presents Initial Clinical Results for ENMD-2076
6. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
7. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
8. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
9. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
10. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
11. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... 2014 New ... the Philadelphia Area ... biotechnology company focused on developing pleuromutilins, a new ... caused by resistant gram-positive and gram-negative pathogens, today ... Schmid will remain a member of the ...
(Date:9/3/2014)... ,    ... ~   Kiadis Pharma B.V. ... biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, ... , MD PhD, as its Chief Medical Officer. ... at Ceronco Biosciences. Prior to that he was VP ...
(Date:9/3/2014)... BUDAPEST, Hungary , Sept. 3, 2014 ... hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") ... and license agreement to co-develop and commercialize bremelanotide ... European Union, other European countries and additional selected ... with a strong focus in female health and ...
Breaking Medicine Technology:Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 2Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 3Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 2Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 3Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 4Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 5
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
(Date:9/3/2014)... Seattle, Wa (PRWEB) September 03, 2014 ... And Body,” a new report created by Tiffany Chou ... for dealing with skin problems including wrinkles and ... report, people will discover some common causes of wrinkles ... repeated facial expressions ,     Sun exposure: excessive exposure ...
(Date:9/3/2014)... Washington has many auto accidents every ... and have severe consequences as they impact the lives ... discusses how they handle these difficult cases . ... Firm, has worked with trucking accident litigation cases for ... usually backed by multiple lawyers and lots of money, ...
(Date:9/3/2014)... 03, 2014 In light of the ... Flood Law Group , a nationally esteemed personal injury ... the latest information is extremely important. The firm ... spreading awareness by sponsoring a website, designed as a ... their legal right to financial compensation. , Among those ...
(Date:9/3/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Pedigree nutrition for dogs . , Mars ... Pedigree Adult Complete Nutrition dry dog food products are ... material. The reason for the recall is that the product ... packages during the production process. These fragments may present a ...
(Date:9/3/2014)... Columbus, OH (PRWEB) September 03, 2014 ... in quality living options and innovative services for older ... Sarah Moore Health Care Center , (Sarah Moore ... 20 years of experience in the health care industry, ... facilities in Ohio including the MacIntosh Company and HCR ...
Breaking Medicine News(10 mins):Health News:“Home Remedies For Wrinkles And Age Spots On Face And Body,” A New Report On Vkool.com, Reveals Natural And Effective Methods For Dealing With Skin Problems 2Health News:Trucking Litigation Cases are Discussed in Recent Article from The Jones Firm 2Health News:Flood Law Group Spreads Awareness in Wake of Most Recent GM Recall Announcement 2Health News:Pedigree Adult Complete Nutrition for Dogs Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Arnett to Lead Delaware’s Sarah Moore Health Care Center 2
... According to it, the packaging or covering on the ... they claim to be able to cure. ... area of licensed medicines, the National Rules System was ... no scientific proof to confirm their claims will be ...
... study by the UC Davis researchers states that children from ... choosing better after school snacks. // ,The study by ... September issue of the American Journal of Public Health, has ... the vending machines aren't the only places that need to ...
... an increased risk of developing lymphoma and leukemia. The ... pain does have the risk of cancer. //Researchers speculate ... alpha (TNFá) antagonists, a type of biologic DMARD may ... which work by attaching to and impeding chemical messengers ...
... and vegetable juices may have the unique property or reducing the ... examined more than 2,000 people in the study, which appears in ... ,The researchers found that the risk of Alzheimer's was reduced by ... least three times a week as compared to those who drank ...
... past decade saw a decrease in traumatic head injuries ... according to a new report released on Wednesday.// ... hospital admissions for traumatic head injuries from 1994 to ... 35 per cent since 1994, with children and youth ...
... Research Institute are optimistic about a visual device that may ... , ,During a study to gauge the ... was a marked increase in the way the visually impaired ... which comprises of a small camera, pocket-sized computer and see-through ...
Cached Medicine News:Health News:Doctors worried about Homeopathic licensing 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 3Health News:RA Drugs Not Implicated In Cancer 2
... synergy T-EP Developed in collaboration with ... and an exceptionally high standard of ... Multimedia technology and design expertise to ... 2, 5 or 10-channel Medelec Synergy ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... of the MYOHANDY family are probably ... MYOQUICK - SystemPLUS line. Based on ... systems of the ISA 100x EP ... ISA 1002 EP) , 4 channels ...
Medicine Products: